Stockreport

Is Zevra Therapeutics Attractively Priced After Recent Rare Disease Pipeline Progress? [Yahoo! Finance]

Zevra Therapeutics, Inc.  (ZVRA) 
PDF The stock has been choppy in the short term, with the share price down around 4.4% over the last week and 6.2% over the past month, but still showing a strong 84.7% gai [Read more]